<div id="readability-page-1"><p>Banque Cantonale Vaudoise raised its stake in shares of  Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 127.1% in the fourth quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 11,037 shares of the biopharmaceutical company's stock after buying an additional 6,177 shares during the period. Banque Cantonale Vaudoise's holdings in Alnylam Pharmaceuticals were worth $4,390,000 as of its most recent SEC filing.</p><ul><li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li></ul><p>A number of other institutional investors also recently modified their holdings of ALNY. Root Financial Partners LLC acquired a new stake in shares of  Alnylam Pharmaceuticals during the 3rd quarter valued at $25,000.  Caitong International Asset Management Co. Ltd acquired a new stake in shares of  Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000.  Ameriflex Group Inc. acquired a new stake in shares of  Alnylam Pharmaceuticals during the 3rd quarter valued at $32,000.  Aster Capital Management DIFC Ltd acquired a new stake in shares of  Alnylam Pharmaceuticals during the 3rd quarter valued at $36,000.  Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of  Alnylam Pharmaceuticals during the 3rd quarter valued at $39,000. Institutional investors and hedge funds own  92.97% of the company's stock. </p><h2>Insider Activity</h2><p>In other news, insider Melissa Mclaughlin sold 2,286 shares of the company's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the transaction, the executive vice president owned 21,860 shares of the company's stock, valued at approximately $6,989,297.80. This trade represents a 7.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 21,255 shares of company stock worth $6,930,337. Insiders own  0.86% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><ul><li>3 biotech powerhouses poised to thrive amid sector rebound</li></ul><p>Several equities research analysts have recently issued reports on ALNY shares. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, February 17th. Bank of America  reiterated a &#34;buy&#34; rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Jefferies Financial Group  reaffirmed a &#34;hold&#34; rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a &#34;sell (d+)&#34; rating to a &#34;hold (c-)&#34; rating in a research note on Monday, May 4th. Finally, Freedom Capital raised shares of Alnylam Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 17th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $463.13.</p><p><b>View Our Latest Analysis on Alnylam Pharmaceuticals</b></p><h2>Alnylam Pharmaceuticals Stock Up 1.4%</h2><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p>Shares of Alnylam Pharmaceuticals stock opened at $298.48 on Thursday. The stock has a market capitalization of $39.85 billion, a P/E ratio of 81.55 and a beta of 0.31. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The stock has a 50 day moving average price of $312.06 and a two-hundred day moving average price of $361.02. Alnylam Pharmaceuticals, Inc. has a 12-month low of $284.19 and a 12-month high of $495.55. </p><p>Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping analysts' consensus estimates of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business's revenue was up 96.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.44) EPS.  Equities analysts expect that  Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current year. </p><h2>About Alnylam Pharmaceuticals</h2> (Free Report)<p>Alnylam Pharmaceuticals, Inc <span>NASDAQ: ALNY<span></span></span> is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.  </p><p>Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.</p><h2>See Also</h2><ul><li>Five stocks we like better than Alnylam Pharmaceuticals</li><li>From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook</li><li>AI Consolidation Begins: Blackstone &amp; Google Forge an AI Empire</li><li>USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms</li><li>3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALNY

SBIO

<p>Banque Cantonale Vaudoise increased its stake in Alnylam Pharmaceuticals by 127.1% in Q4, now holding 11,037 shares valued at $4.39 million. Other institutional investors also acquired stakes in the company. Insider trading activity included sales by executives to cover tax obligations. Analysts have set new price targets, with a consensus rating of 'Moderate Buy' and an average target price of $463.13.</p>

Market Beat

Alnylam Pharma

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

Direxion Daily Biotech Top 5 Bull 2X ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

Bank of America

Jefferies Financial

Argenx

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Banque Cantonale Vaudoise Has $4.39 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY